Dr. Richard Manning is an economic expert focused on high-stakes disputes in the life sciences industry, including biopharmaceuticals (spanning innovator, generic, biosimilar, and over-the-counter products), medical devices, and related healthcare sectors, including animal health. He provides expert testimony and economic analysis in complex litigation and arbitration involving valuation, damages, intellectual property, merger-related disputes and antitrust.
Washington, DC
Dr. Manning’s work spans the full product lifecycle—from early-stage development through commercialization—and is distinguished by its focus on the economics of innovation, regulation, and market access. His analyses frequently address how clinical development risk, FDA approval processes, pricing and reimbursement dynamics, and intellectual property protection affect valuation and damages.
He has testified in U.S. District Court, the Delaware Court of Chancery, U.S. Bankruptcy Court, the United States Patent Trial and Appeal Board, and international arbitration venues including the International Chamber of Commerce. His recent matters include high-profile life sciences disputes involving valuation, trade secrets, and M&A-related earnout provisions, including serving as the plaintiff’s damages expert in Fortis Advisors LLC v. Johnson & Johnson, a case involving one of the largest earnout awards in Delaware Chancery history. Recently, he also testified successfully on damages for the defendant in a high-stakes biotechnology trade secret misappropriation matter.
In addition to damages and valuation matters, Dr. Manning is engaged on antitrust, competition, and policy issues affecting life sciences markets.
His work has been cited by the Congressional Budget Office and in the Wall Street Journal, reflecting its relevance to broader industry and policy discussions.
Prior to consulting, Dr. Manning spent 14 years as an executive in multinational pharmaceutical companies, including leadership roles at Pfizer and Merck, where he led economic analysis and strategy development on issues including pricing, intellectual property, regulatory developments, and healthcare policy. This experience informs his ability to connect rigorous economic analysis with real-world industry decision-making.
Earlier in his career, Dr. Manning was a faculty member at Brigham Young University and a visiting professor at the University of Chicago, focusing on industrial organization and the economics of regulation.
He holds a PhD in Economics from the University of Chicago and a BA in Economics from Brigham Young University.
Secretariat and Six Experts Earn Recognition in the 2026 IAM Patent 1000 Listing
Secretariat and six of the firm’s intellectual property experts have been recognized in the 2026 IAM Patent 1000 for their market-leading patent litigation expertise.
Secretariat’s Testimony Leads to Nearly $811 Million Award in Landmark Life Sciences M&A Dispute
A Secretariat expert team, led by Dr. Richard Manning, provided key damages calculations and expert testimony in the precedent-setting Delaware Court of Chancery decision that secured an approximately $811 million award for Fortis Advisors, representative of Auris Health’s former stockholders, in a post-closing earnout dispute with Johnson & Johnson (J&J).
Nine Secretariat Experts Recognized in the 2025 IAM Patent 1000 Listing
Nine Secretariat intellectual property experts have been recognized in the IAM Patent 1000: The World’s Leading Patent Professionals 2025 for their world-class patent litigation expertise.